about
Microvascular and mitochondrial dysfunction in the female F1 generation after gestational TiO2 nanoparticle exposure.Transport of digoxin-loaded polymeric nanoparticles across BeWo cells, an in vitro model of human placental trophoblast.Drug delivery for the treatment of endometriosis and uterine fibroids.Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.Nanomedicine applications in women's health: state of the art.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nanomedicine for uterine leiomyoma therapy
@en
Nanomedicine for uterine leiomyoma therapy.
@nl
type
label
Nanomedicine for uterine leiomyoma therapy
@en
Nanomedicine for uterine leiomyoma therapy.
@nl
prefLabel
Nanomedicine for uterine leiomyoma therapy
@en
Nanomedicine for uterine leiomyoma therapy.
@nl
P2093
P2860
P356
P1433
P1476
Nanomedicine for uterine leiomyoma therapy
@en
P2093
Erik Rytting
Gokhan Kilic
Kathleen Vincent
Massoud Motamedi
P2860
P304
P356
10.4155/TDE.12.144
P577
2013-02-01T00:00:00Z